Treatment with high doses of anticoagulants can reduce mortality by 30%.

Anticoagulant treatment At high doses it can reduce the death rate by 30% and the need for intubation by 25% in hospitalized coronavirus patients who are not in critical condition, compared to standard treatment, What is a low dose of anticoagulant?. These are the results of the international study “Freedom COVID”, which was presented Monday in the framework of American Congress of Cardiology in New Orleans (USA). previously coordinated investigation HM Hospitals Research Foundation (FiHM) and that, they maintain, from the private hospital group, it could change the current management of non-critical coronavirus patients.

In the study 76 hospitals from ten countries participated. in Spain, led by the HM Hospitals Research Foundation, with its Scientific Director, Dr.. Jose Maria Castellano, as the principal investigator. The International Federation of Billing Management (FiHM) coordinated centers and patients who took part in the research, which, Dr. Castellano explains, provides new evidence for improving the management of COVID-19 patients and shows that high-dose anticoagulants can improve survival, Specifically in hospitalized patients with lung involvement Without reference to admission to the intensive care unit.The main author of “Freedom” is physician Valentine FosterDirector General of the National Cardiovascular Research Center (CNIC), and Chair Mount Sinai heart And the chief physician Mount Sinai HospitalI (New York), who presented the results of this experiment -publish it Journal of the American College of Cardiology (JACC) – in American College of Cardiology.

Five Spanish hospitals

At the beginning of the epidemic, Valentine Foster, a doctor, catches up That many patients in the hospital COVID-19 They developed high levels of blood clots life-threatening and has elected to begin this trial between August 2020 and September 2022. 3398 adult patients were recruited hospitalized with coronavirus (average age 53) from 76 hospitals in 10 countries, Among them is Spain.

Patients are not admitted intensive care unit or intubated, and nearly half of them, showed signs of disease that had affected their lungs, causing Acute respiratory distress syndrome (ARDS). “This is the first study to show that higher doses of anticoagulants can improve survival in these patients, an important finding because deaths from COVID-19 are still frequent,” the cardiologist highlights.

The participants were randomly selected To receive doses of three different types of blood thinners Within 24-48 hours of admission to the hospital f observed for 30 days. Their follow-up showed that treatment with prophylactic anticoagulants (low doses) was associated with better outcomes, in and out of the intensive care unit, among patients hospitalized with coronavirus. The researchers also note that therapeutic (high-dose) anticoagulants may produce better results.

FiHM’s participation It served as a link for managing the patient group of five Spanish hospitals: HM Sanchinarro, HM Montepríncipe, HM Torrelodones and two general hospitals, Complejo Hospitalario de Navarra and Infanta Leonor University Hospitalin Vallecas, Madrid. The HM Hospitals Group, through FiHM, highlights that it has participated in most of the clinical trials that provided evidence in each of the treatments currently used in coronavirus patients. As in the case of various vaccinations in adults, children and pregnant women.